



GSI Helmholtzzentrum für Schwerionenforschung GmbH




GSI Kolloquium

Nuclear aspects in hadrontherapy

Vincenzo Patera

Universita' di Roma "La Sapienza" & INFN

GSI, Darmstadt, 24 nov 2015



Outline

Bouncing from fundamental physics to applied physics and back...
A spot-like, phenomenological, detector oriented view to the impact of nuclear interactions (fragmentation) on particle therapy

**(Short) Introduction to
particle therapy**

**Proton beam
& target
fragmentation**


Dose Release

**Nuclear
Interactions
(fragmentation,
excitation..)**

**Neutron
production**


**Range
Monitoring**

Summary & conclusions



Outline

Bouncing from fundamental physics to applied physics and back...
A spot-like, phenomenological, detector oriented view to the impact of nuclear interactions (fragmentation) on particle therapy



The conventional RT


The photon (and e^-) beams are the most common in RT. Cheap, small, and reliable.



The energy release is not suitable to release dose in a deep tumor.


But the use of sophisticated imaging (CT), superposition of several beams, computed optimization, multi-leaves collimators and >40 year of R&D make IMRT effective and widespread

Dose-depth relation for γ and e^-





Particle therapy vs Photon RT



The highest dose released at the end of the track, sparing the normal tissue



- Beam penetration in tissue function of the beam energy
- Dose decrease rapidly after the BP.
- Accurate conformal dose to tumor with Spread Out Bragg Peak (active scanning!)





Photons vs Particle saga...



Particle therapy can easily show better selectivity wrt photon techniques...


Yet, randomized clinical trials seem the only commonly accepted method to assess eventual superiority of PT technique



Radiosurgery

Particle therapy

Charged Particle Therapy in the world



~2014: 122499 treated patients: 105743 with p, mainly in USA, 53532
13119 with ^{12}C , mainly in Japan, 10993;
+ 46,000 in the past 5 years \approx 10,000 patients per year

Yet a
minimal
fraction of
photon RT



Which is the right beam for therapy?

Beam lateral deflection

As far as money is the main concern.. protons win easily!


If we come to effectiveness, the landscape can change.

For instance, concerning the beam selectivity, comparing lateral deflection heavier ions have less multiple scattering




Heavier than proton? Maybe yes (RBE..)

M.Kramer et al. JoP 373 (2012),



TRAX
code

- The heavier ions are much better at killing the tumor cells with respect to the X rays (and p) for a given → high RBE
- Heavier ions have better plateau/peak ratio (less dose to the healthy tissue in a treatment) wrt to proton beams




$$RBE = \frac{D_{\gamma}}{D_{ion}} \Big|_{Isoeffect}$$


OER and ^{16}O beam

The high LET of the ^{16}O beam is effective against radio-resistant hypoxic tumors (low Oxygen Enhancement Ratio)

Bassler et al., Acta Oncol 2013




M.Kramer et al. JoP 373 (2012),



Full treatment or simple boost session with ^{16}O with hypoxic can be a clear improvement with respect to conventional Radiotherapy

Outline

Accuracy in the dose release, radio biological effectiveness and effectiveness on radio-resistant hypoxic tumors suggest an escalation to **higher Z beam**. But the nuclear interaction itself sets a limit ...



Heavier is better?




Fragmentation!

Dose release in healthy tissues with possible long term side effects, in particular in treatment of young patients → must be carefully taken into account in the Treatment Planning System

- ✓ Production of fragments with higher range vs primary ions
- ✓ Production of fragment with different direction vs primary ions


- ✓ *Mitigation and attenuation of the primary beam*
- ✓ *Different biological effectiveness of the fragments wrt the beam*



Exp. Data (points) from Haettner et al, Rad. Prot. Dos. 2006

Simulation: A. Mairani PhD Thesis, 2007, Nuovo Cimento C, 31, 2008

The abrasion-ablation paradigm



- Fragments from quasi-projectile have $V_{\text{frag}} \sim V_{\text{beam}}$ and narrow emission angle. Longer range than beam
- The other fragments have wider angular distribution but lower energy. Usually light particles (p,d,He)
- The dose beyond the distal part comes from the quasi projectile contribution. Wide angular halo from the rest of the process

Fragments from ^{12}C beam ($E_{\text{kin}}=400 \text{ AMeV}$) on ^{12}C



The $Z>2$ produced fragments approximately have the same velocity of the ^{12}C beam and are collimated in the forward direction

The protons are the most abundant fragments with a wide β spectrum $0<\beta<0.6$ and with a wide angular distribution with long tail

The $Z=2$ fragment are all emitted within 20° of angular aperture


The dE/dx released by the fragment spans from ~ 2 to $\sim 100 \text{ m.i.p.}$

Do not trust MC too much!



Data - MC comparison: ^{12}C ions

Differential/double- differential quantities (vs angle and/or energy) \rightarrow large discrepancies found!




NB: the accuracy on delivered dose MUST be of the order of few %

Some MC benchmarks:
Sommerer et al. 2006, PMB
Garzelli et al. 2006, JoP
Pshenichnov et al. 2005, 2009
Mairani et al. 2010, PMB
Böhlen et al. 2010, PMB
Hansen et al. 2012, PMB

What we still miss to know about light ions fragmentation in 2015?

Data exist at 0° or on thick target. But we need to know, for any beam of interest and on thin target:


- Production yields of $Z=0,1,2,3,4,5$ fragments
- ✗ $d^2\sigma/d\theta dE$ wrt angle and energy, with large angular acceptance
- ✗ For any beam energy of interest (100-300 AMeV)
- ✗ Thin target measurement of all materials crossed by beam



Not possible a complete DB of measurements

We need to train a nuclear interaction model with the measurements!!

Recent thin target, Double Diff Cross Section C-C measurements



The community is exploring the interesting region for therapeutic application, in particular for the ^{12}C beam. Yet there is a lot of energy range to explore in the range 150-350 AMeV (i.e. 5-17 cm of range...)

LNS 62AMev C beam
See M. De Napoli talk
in this session (2009)

GANIL 95AMev C
beam - E600
collaboration (2011)

GSI 400Mev C beam
FIRST experiment
(2011->??)

FIRST setup @GSI

^{12}C beam
400 A MeV

Start Counter (SC): thin scintillator. N_c , start of ToF and trigger


Beam Monitor (BM): drift chamber for beam direction and impact point measurements

Target (TG): A 0.5 mm gold target (4,5 M events) and a 8 mm composite target (C/O/Cr/La/P/Ca) = (35/47/8/7/2/1)% (24 M events)



Vertex Detector (VTX): pixel silicon detector. Tracks direction θ ($\pm 40^\circ$), ϕ (2π)

Proton Tagger (PT): plastic scint. and scint. fibers. Position, ToF, dE/dX for $\theta > 5^\circ$ H & He

ToF Wall (TW): two layers of plastic scint. Impact position (x, y, z), Z_ID , ToF for trks $\theta < 5^\circ$



R. Pleskac, 2012, NIM A
Z. Abou-Haidar, 2013, JINST
R. Rescigno, 2014 NIM A
G. De Lellis, 2015 JMST
M. Toppi, submitted PRC
(gold target)



Outline

The nuclear interaction of the beam prevents the use of beam heavier than Oxygen and must be taken into account in TPS.. But can be of help for another crucial aspect of particle therapy: range monitoring

(Short) Introduction to
particle therapy

Proton beam
& target
fragmentation

Dose Release

Nuclear
Interactions
(fragmentation,
excitation..)

Neutron
production

**Range
Monitoring**




Summary & conclusions



Dose profile in PT

Why is so crucial to monitor the dose in particle therapy with respect to photon RT? It is like firing with machine-gun or using a precision rifle..
Inhomogeneities, metallic implants, CT artifact, HU conversion, inter session anatomical/physiological changes-> range variations

Effect of density changes in the target volume



The range verification problem

AAPM, August 2012

Delegates were asked what they considered as the main obstacle to proton therapy becoming mainstream:


- 35 % unproven clinical advantage of lower integral dose
- 33 % range uncertainties
- 19 % never become a mainstream treatment option

RESEARCH

Aug 22, 2012

Will protons gradually replace photons?

The dose distribution advantages offered by proton therapy, particularly with the introduction of pencil-beam scanning, have stimulated increasing interest in this modality. But is the large capital expenditure required to build a proton therapy facility hindering the widespread implementation of this technique? And how big a problem is range uncertainty, which can prevent proton therapy from meeting its full potential?




Protons versus IMRT


Accounting for uncertainties in the clinical practice

[Tang et al. 2012]

Current approach:
*Opposed fields,
overshooting*



Desirable approach:
*Different beam angles and
no overshooting*



Protons

Spec's of particle therapy monitor

In PT the beam is easily monitored in the transverse direction but longitudinally stops inside the patient. An ideal PT monitor device should fulfill the following spec's:


- Measure shape and (if possible) the absolute value of dose release to check the agreement between the planned target volume and the actually irradiated volume
- Measurements and feed-back should be provided during the treatment (in-beam). Even better if the monitor response can follow the irradiation scan on line
- Must relay on the signal by secondary particles, generated by the beam, that comes out from the patient
- Must deal with the background of the "non signal" secondaries that come out

Help from Nuclear Physics: exploiting secondary products

The therapeutic beam is absorbed inside the patient: a monitor device can rely on secondaries, generated by the beam coming out from the patient. The p, ^{12}C beams generate a huge amount of secondaries: **prompt γ s**, **PET- γ s**, **neutrons** and **charged particles/fragments**


Activity of β^+ emitters is the baseline approach

- Isotopes of short lifetime ^{11}C (20 min), ^{15}O (2 min), ^{10}C (20 s) with respect to conventional PET (hours)
- Low activity asks for quite a long acquisition time (some minutes at minimum) with difficult in-beam feedback
- Metabolic wash-out, the β^+ emitters are blurred by the patient metabolism






In-Vivo range measurement with PET: workflow and potential

W. Enghardt et al.: Radiother. Oncol. 73 (2004) S96



Spotting structures with β^+ activity measurement in-beam (proton beam at CNAO)




A PMMA phantom with air holes in two different positions was irradiated with protons.


A uniform 2 Gy dose was delivered to a 4x4x6 cm³ PTV.

The proton TP is composed of 34 energy layers with energies ranging from 62 MeV up to 116 MeV/u.

V. Rosso et al,
Submitted to Nucl. Instr. & Meth.




Each profile was calculated over a volume that passes through one air cavity. The reported profiles correspond to 360 s data acquisition and the profiles were normalized to the same area.






Non PET techniques: simplified overview

- Several different solutions under study
- Unique clinical solution not yet established
- Suitable detectors not commercially available
- Impressive number of physicists/institutions at work





The prompt photons solution




Courtesy of
Alfredo Ferrari

[sketch and exp. data taken from F. Le Foulher et al IEEE TNS 57 (2009), E. Testa et al, NIMB 267 (2009) 993. exp. Data reevaluated in 2012 with substantial corrections]






The prompt γ emission: summary





- The gamma are quite copiously produced by proton and ^{12}C beam by nuclear excitation. 😊
- The emission region stretches along all the beam path but has been shown to ends near the Bragg peak for both beams. 😊
- It's not simple backpointing the γ direction: the γ energy is in the 1-10 MeV range \rightarrow much more difficult to stop and collimate with respect to ^{99}Tc 144 KeV γ in standard SPECT imaging ☹️
- Huge background (beam, energy and site specific) due to neutrons & uncorrelated γ s produced by neutrons. TOF not easy to exploit in clinical practice ☹️





Influence of TOF on PG profiles (collimated cameras)

160 MeV protons in PMMA
IBA C230 cyclotron



Roellinghoff PMB 2014

310 AMeV carbon ions in PMMA



TOF : mandatory for carbon ions

M. Pinto, submitted New J Phys



Courtesy of D. Dauvergne

Range monitor for proton beam: the slit camera

Optimized on proton beam

Several groups working also on:

- electronic collimated (Compton) camera
- Multi-slit collimated camera





Possible clinical solution envisaged for proton beam, but what about heavier beam (¹²C)? LET grows as Z^2 and the nuclear interaction increase with A . Thus, for the given dose, ¹²C gives:

- less prompt γ than proton
- more background than proton

Secondary @ HIT from ^4He , ^{12}C , ^{16}O beams


- He, C, O beams with therapeutical energy
- thick PMMA target with **fixed** distance between BP and PMMA exit window




- ✓ BGO detectors for forward $[0^\circ - 30^\circ]$ fragmentation studies
- ✓ pixelated LYSO detectors for PET monitoring
- ✓ {DCH} + {LYSO} setup for prompt- γ and charged particles studies
- ✓ Thin plastic scintillators have been used for ToF and dE measurements.

Non proton beams: Prompt γ vs E_{kin}

- Approximate linear scaling with $E_{\text{kin}}/\text{nucleon}$ irrespectively of A
- Is the number of the de-excitation γ proportional to the nuclear collisions of the beam?



Non proton beams : something else useful? Charged fragments (protons)



BUT...

- They are forward peaked
- Energy threshold to escape the patient ~ 80-90 MeV
- They suffer multiple scattering inside the patient -> worsen the back-pointing resolution



Charged secondaries have several nice features as

- The detection efficiency is almost one
- Can be easily back-tracked to the emission point -> can be correlated to the beam profile & BP

MC highly unreliable, probing the very tail of the angular distribution of secondary

Secondary proton: angle vs energy

The protons could be a possible candidate for beam imaging... if they can escape the patient!! ($E_{\text{kin}} > 100$ MeV)





The proton flux at large angle is mainly made by low energy particles.. Can be of any use for monitoring???

WATCH OUT!! How much are MC reliable at the moment? They are rapidly improving, but...



Charged secondary emitted from BP ?

- Measurements at LNS (Catania) ^{12}C beam @ 80 MeV/nucleon. Range in PMMA phantom ~ 1 cm.
- Corresponds to the last part of the path in the patient of higher energy, longer range pencil beam \rightarrow signal from BP region
- Moving the target the charged signal follows





Charged secondary from BP ?

- Measurements at LNS (Catania) ^{12}C beam @ 80 MeV/nucleon. Range in PMMA phantom ~ 1 cm.
- Corresponds to the last part of the path in the patient of higher energy, longer range pencil beam \rightarrow signal from BP region
- Moving the target the charged signal follows



Charged secondary from BP ?





- Measurements at LNS (Catania) ^{12}C beam @ 80 MeV/nucleon. Range in PMMA phantom ~ 1 cm.
- Corresponds to the last part of the path in the patient of higher energy, longer range pencil beam \rightarrow signal from BP region
- Moving the target the charged signal follows



charged secondaries & ^{12}C beam radiography

L. Piersanti et al. PMB, 2014

Charged secondaries produced at 90° wrt the beam from PMMA target on 220 AMeV. ^{12}C beam at GSI



Carbon beam @90° (reference runs)

Charged secondaries monitoring



A non negligible production of charged particles at large angles is observed for all beam types.

The emission shape is correlated to the beam entrance face and BP position as already measured with ^{12}C at GSI.

(Piersanti et al. PMB, 59 (2014))

C @120MeV

Charged from
HIT beam
(2014)



Carbon beam @90° (reference runs)

Charged secondaries monitoring

A non negligible production of charged particles at large angles is observed for all beam types.



The emission shape is correlated to the beam entrance face and BP position as already measured with ^{12}C at GSI.

(Piersanti et al. PMB, 59 (2014))

C @180MeV

C @120MeV

Charged from
HIT beam



Carbon beam @90° (reference runs)

Charged secondaries monitoring



A non negligible production of charged particles at large angles is observed for all beam types.

The emission shape is correlated to the beam entrance face and BP position as already measured with ^{12}C at GSI.

(Piersanti et al. PMB, 59 (2014))



Charged from
HIT beam




Carbon beam @90° (reference runs)

Charged secondaries monitoring



A non negligible production of charged particles at large angles is observed for all beam types.

The emission shape is correlated to the beam entrance face and BP position as already measured with ^{12}C at GSI.

(Piersanti et al. PMB, 59 (2014))



Charged from
HIT beam



Helium beam @90°

Charged secondaries monitoring

A non negligible production of charged particles at large angles is observed for all beam types.

The emission shape is correlated to the beam entrance face and BP position as already measured with ^{12}C at GSI.

(Piersanti et al. PMB, 59 (2014))




PMMA

PMMA



PMMA

X and Y projected at PMMA



Charged from
HIT beam


ADC count for lyso vs TOF_unslew




Secondary proton: energy distribution

Only a fraction of the p flux can exit the patient.. 80-90 MeV are needed in the worst case (deep tumor at 8-9 cm from skin)

^{12}C @220 AMeV L.Piersanti et al. PMB, 2014



^4He @145 AMeV (HIT) to be sub. to PMB




Secondary emission point, BP and the patient

The materials crossed to exit from the patient modifies the detected distribution (absorption & MS). **Similar approach of PCT needed: exploiting the knowledge of the pencil beam transverse position and the CT deconvolute the emission shape**


Measured emission shape of protons outside a 5 cm thick PMMA at 90° wrt the direction of 220 AMeV ^{12}C beam

L. Piersanti et al. PMB, 2014




Simulated emission distribution shape of protons as detected outside different PMMA thickness at 30° wrt the direction of 95 AMeV ^{12}C beam

E. Testa et al Phys. Med. Biol. 57 4655




detector: which & where?

Any large area tracking detector!! The resolution of the back-tracking is limited by the multiple scattering in the patient, not by the detector resolution..



Backpointing error due to MS for proton crossing 10 cm tissue



Small angle

- higher momentum
-> less MS
- Higher statistic
- Back-tracking is much worse

Large angle

- Optimal back-tracking
- lower momentum
-> more MS
- Less statistics

The *InSide* Project


Prompt secondary particles
emission

Tracker +
Calorimeter =
DOSE PROFILER

β^+ activity
distribution
IN-BEAM PET
HEADS

INnovative **S**olutions for
In-beam **D**osim**E**try in
Hadrontherapy

- ❑ integrated in treatment room
- ❑ operated in-beam
- ❑ provide an **IMMEDIATE** feedback on the particle range



InSide @ CNAO

PRIN + Centro
Fermi + INFN
project




P. Cerello
S. Coli
E. Fiorina
G. Giraudo
F. Pennazio



N. Belcarì
G. Bisogni
N. Camarlinghi
A. Del Guerra
S. Ferretti
E. Kostara
A. Kraaen

N. Marino
M. Morrocchi
M.A. Piliero
G. Pirrone
V. Rosso
G. Sportelli



C. Peroni
A. Rivetti
R. Wheadon
A. Attili,
S. Giordanengo



E. De Lucia
R. Faccini
P.M. Frallicciardi
M. Marafini
C. Morone

V. Patera
L. Piersanti
A. Sarti
A. Sciubba
C. Voena





F. Ciciriello
F. Corsi
F. Licciulli
C. Marzocca
G. Matarrese



G. Battiston
S. Muraro
P. Sala


The INSIDE Project: PET system



- ❖ Detectors to measure the 511 keV back-to-back photons in order to reconstruct the β^+ activity map;
- ❖ Two planar panels: 10 cm x 20 cm wide \Rightarrow 2 x 4 detection modules;



- Each module is composed of a pixelated LYSO matrix 16 x 16 pixels, 3 mm x 3 mm crystals (pitch 3.1mm);
- LYSO matrix readout: array of SiPM (16x16 pixels) coupled one-to-one.

The **resolution** of the two PET heads system in the β^+ activity reconstruction map is expected to be between 1 and 2 **mm (FWHM)** in beam direction.




The INSIDE Project: Dose Profiler

- ❖ The Dose Profiler aim is to back tracks the secondary particles (p,d,t and prompt photons) and reconstruct their emission point together with their flux.




detector at 60°
to increase the
secondary
charged
particles rate

INSIDE Profiler: dual mode detector




- Compton camera for prompt photons ($E_\gamma \sim 1-10$ MeV)
- Tracking device for charged secondaries ($E_{\text{kin}} \sim 30-130$ MeV)

- Heavy charged secondary cross all TRK planes up to LYSO crystals
- Electrons from Compton event have winding tracks (mul. scatt.) and are not detected in the LYSO




The INSIDE Project: Dose Profiler


Fiber + calorimeter
structure



SiPM readout electronics



- ✓ Expected 3mm accuracy on a slice on ^{12}C beam
- ✓ Calibration at Trento proton beam during 2016
- ✓ Test at CNAO with phantom end 2016- first 2017



Mechanic structure

Outline

In clinical practice the proton beam is handled qualitatively as the photon beam (**RBE=1.1**). But the protons **DO HAVE** nuclear interaction with the patient that could have clinical impact

(Short) Introduction to
particle therapy

**Proton beam
& target
fragmentation**

Dose Release

**Nuclear
Interactions
(fragmentation,
excitation..)**

Range
Monitoring

Neutron
production


Summary & conclusions

Target fragmentation & proton RBE


Currently the contribution of target fragments and of the increasing RBE near the PB is implicit (ICRU recommendation $RBE=1.1$)

Lately has been pointed out possible impact of variable proton RBE on clinical NTCP values

RBE=1.1



Variable RBE




The differences in DVHs and dose distributions are also translated into different NTCP values, shown in Table III. As an example, the probability of necrosis in the brain stem is estimated in case1 to 0.84% for the IMRT plan and 0.57% for the proton plan when assuming a RBE equal to 1.1. However, when assuming a variable RBE the probability increases to 2.13%. Equivalently, the probability for blindness increases from 1.13% ($RBE = 1.1$) to 4.21% (variable RBE) for protons compared to 1.21% for photons for the optic nerve. The same tendency of estimating a lower NTCP for protons compared to photons when having RBE equal to 1.1, but obtaining a higher NTCP compared to photons when assuming a RBE distribution is also observed for the chiasm and for the other brain cases (see Table III).

Target fragmentation & PT: is an issue at all?

The target fragmentation could be relevant (only?) for proton beam treatment. The proton inelastic scattering on patient nuclei (C,O,N) produces $Z \leq 8$ fragments with low energy \rightarrow very high LET and very good at cell killing (very high RBE)


Example : analytic approximation of $p \rightarrow H_2O$ @250 MeV



- In water, about **1% cm⁻¹** of protons undergo inelastic nuclear interactions
- In a typical treatment, this corresponds to about **20% of the primary beam**
- **60%** of the energy deposited by recoil in charged fragments
- **40%** in neutrons and photons out of the field

Target fragmentation & PT: where is an issue?

Target fragmentation in proton therapy: gives contribution also outside the tumor region!



Focus on $p \rightarrow X$ (C,O,N) scattering & heavy fragment production @100-250 MeV

The proton-nucleus elastic interaction and the light fragment production, namely p,d,t and He(?), are quite well known..

$P \rightarrow H_2O$ @ 200 MeV

BUT.....


"Heavy" ($A \geq 4$)
fragment emission
energy and angle
largely unknown.

Very low energy-
short range
fragments.

Fragment	E (MeV)	LET (keV/ μ m)	Range (μ m)
^{15}O	1.0	983	2.3
^{15}N	1.0	925	2.5
^{14}N	2.0	1137	3.6
^{13}C	3.0	951	5.4
^{12}C	3.8	912	6.2
^{11}C	4.6	878	7.0
^{10}B	5.4	643	9.9
8Be	6.4	400	15.7
6Li	6.8	215	26.7
4He	6.0	77	48.5
3He	4.7	89	38.8
2H	2.5	14	68.9

p → Brain scattering @ 200 MeV

Also FLUKA MC suggest a **low-energy, short range** production of heavy frag: 200 MeV p on "BRAIN" : production of He & C



Direct measurements strategy

For RBE exploitation $d\sigma/dE$ is compulsory !!

- The fragments travel few μm in the target-> difficult to directly detect them, even for very thin target (10 μm ?)
- The energy loss of the fragment in the target would be substantial and would be a severe systematic to be evaluated
- Such a very thin target produces very few events -> very careful control of the background.
- Possible solution from JET target techniques, where the target is a focused flux of gas crossing the beam in vacuum: difficult and expensive

Inverse kinematic strategy

Since shooting a proton with a given β ($E_{\text{kin}}=200 \text{ MeV} \rightarrow \beta=0.6$) on a patient (C,O,N nuclei) at rest gives no detection opportunity... **let's shoot a $\beta=0.6$ patient (C,O,N nuclei) on a proton at rest and measure how it fragments!!**

Then if we measure the X-section, provide we apply an inverse velocity transformation, the result should be the same.

- **Use (as patient) beams N, O, C ions with $\beta=0.6 \rightarrow E_{\text{kin}}/\text{nuc}=200\text{MeV}$.**
- **Use a target made of H... but this is difficult! (I will come to this...)**

The heavy fragment (all but p,d,t,He) has $\sim 200\text{MeV}/\text{nucleon}$ kinetic energy and are forward peaked

Inverse kinematics and the target


The target can be thick as few mm, since the fragment range is larger than several cm.

The H target could be a Liquid Hydrogen, but with little non H material on the beam path → cryogenics?

A possible solution is to use twin targets: C and hydrocarbons. The fragmentation cross section can be obtained by subtraction.

Simultaneous double target data taking can to minimize systematic, if the setup has good vertexing capability along beam line



Heavy fragment are forward peaked, must be separated by the beam: very good PID capability



C-H X-section extraction: ^{12}C beam on C, CH_2 target @ 95 A MeV

GANIL experiment of C-C fragmentation. Obtained results for Single and Double Diff. X Section.

- interesting conclusion: X-sections for composite targets can be deduced from the cross sections of elemental targets (-> organic tissues)
- Systematics???



Physicists & the Lord of the Ring...

A lot of colleagues are fan of the Tolkien masterpiece (myself included), but a particular scene from "The return of the King" explains very well the physics attitude community toward a difficult (or impossible) enterprise...

Certainty of death..
Small chance of success..

WHAT ARE WE WAITING
FOR???



New target fragmentation Experiment?

The community is starting to think at target fragmentation experiment: newcomers are welcome !

- Challenging measurement: support by Nuclear Physics Commission of INFN
- A first meeting dedicated to this opportunity/challenge held in Villa Tambosi (TN) in July 2015 , near TIFPA
- Beam available in Europe: HIT, CNAO, GSI(?)

Fragmentati**O**n**O**f **T**arget



A possible setup (FLUKA Simulation)

Scint. Fiber Tracker (INSIDE)

Permanent Magnet (0.5 T)

20 cm

20 cm


C or CH₂ Target

Silicon Pixel (20 μm)
Front Tracker

Silicon Pixel Back
Tracker ("Plume")

0.75 cm

0.75 cm



Outline

Neutron production in PT and long term effect of the dose induced by neutrons on patient has been a long standing “hot” item in the querelle RT vs PT

**(Short) Introduction to
particle therapy**

**Proton beam
& target
fragmentation**

Dose Release

**Nuclear
Interactions
(fragmentation,
excitation..)**

**Range
Monitoring**

**Neutron
production**

Summary & conclusions



Radiotherapy and secondary cancers

Cancer survivors represent about 3.5% of US population

Second primary malignancies in this high-risk group accounts for about 16% of all cancers

Three possible causes:

- Continuing lifestyle

- Genetic predisposition


- Treatment of the primary cancer

Assessment is difficult because of lack of controls

Prostate and cervix cancer: surgery is an alternative

Hodgkin's lymphoma: risk of breast cancer very high

Radiation-induced secondary cancers are mostly carcinomas, but a sarcomas in heavily irradiated sites are also observed





Brenner *et al.*, *Cancer* (2000)

Courtesy M.Durante

PT and pediatric tumors

Eventual secondary effect of diffuse dose are very relevant for pediatric tumor, where the expected life span is longer.

The neutron contribution is particularly difficult to model and to be taken into account in TPS (environment, reflection, beam halo, etc..)




Photons

Protons

	X-ray	IMRT	Proton
CTV	90%	90%	90%
Heart	18.2	17.4	0.1
Right lung	3.5	21.9	0.1
Esophagous	11.9	32.1	10.2
Stomach	3.7	20.6	0.1
Right kidney	3.3	29.8	0.1
Transvers colon	2.6	18.0	0.1

Courtesy of R.Orecchia

Neutrons & Radio/Proton/Carbon therapy



The expected neutron flux dominates, by orders of magnitude, the total secondary flux nearly at all energies.

Neutrons produced by the beam in PT treatments are mainly fast neutrons [20-200 MeV]

Degradation by scattering with patient/materials produces large flux of slow neutrons.



Neutron quest... old saga!




- ✓ Accurate measures of n production X-section by p,¹²C beam on needed materials (O,C), with angle and energy distribution, is still missing.
- ✓ Due to their intrinsic detection efficiency, neutron on line monitoring during PT is particularly difficult, (no directionality, scattering from environment, probabilistic releas of energy, PID?, etc..)

172 MeV
Proton beam


Hultqvist and Gudowska, PMB 55,2010

All particles produced and transported



Gonads ~12 cm from target
Particles flux



All particles produced but no
neutron transported



MOnitor for Neutron Dose in hadrOntherapy

Plastic Scintillator

- $4 \times 4 \times 8 \text{ cm}^3$;
- scintillating fibres $250 \text{ }\mu\text{m}$;
- 160 squared fibres per layer;
- 320 U-V layers;




**TRACKING
the neutron !!**

- ✧ Tracking device for 20:300 MeV neutrons
- ✧ Efficiency in 10^{-2} - 10^{-3} range
- ✧ Funded by MIUR (PRIN) + INFN Young Grant (2016-2018)



MONDO

Impinging neutron kinematic from
double n-p elastic scattering on fiber



Single hit resolution:

$E_{\text{kin}} = 10 - 100 \text{ MeV} \Rightarrow 7-20 \%$

40 hit/cm sampling

Read out by SPAD (digital SiPM)

- **Neutron** $T=[20-200] \text{ MeV}$
Inter. length. $\sim 0.4-1 \text{ m}$
Inter. prob in $0.25 \text{ mm} \sim 10^{-4}$
 $P(\text{single scatt.}) \sim 7\%$

- **Proton range**

$T = 100 \text{ MeV} \Rightarrow 8 \text{ cm}$

$T = 50 \text{ MeV} \Rightarrow 2 \text{ cm}$


$T = 30 \text{ MeV} \Rightarrow 1 \text{ cm}$

$T = 10 \text{ MeV} \Rightarrow 0.1 \text{ cm}$



MONDO

Impinging neutron kinematic from double n-p elastic scattering on fiber



Single hit resolution:

$E_{\text{kin}} = 10 - 100 \text{ MeV} \Rightarrow 7-20 \%$

40 hit/cm sampling

Read out by SPAD (digital SiPM)

- **Neutron** $T=[20-200] \text{ MeV}$
Inter. length. $\sim 0.4-1 \text{ m}$
Inter. prob in $0.25 \text{ mm} \sim 10^{-4}$
 $P(\text{single scatt.}) \sim 7\%$

- **Proton range**

$T = 100 \text{ MeV} \Rightarrow 8 \text{ cm}$

$T = 50 \text{ MeV} \Rightarrow 2 \text{ cm}$

$T = 30 \text{ MeV} \Rightarrow 1 \text{ cm}$



$T = 10 \text{ MeV} \Rightarrow 0.1 \text{ cm}$




MOnitor for Neutron Dose for hadrOntherapy



SPAD Matrix
prototype:
digital output of
the # of SiPM
fired in 10 ns



Photon ReadOut



- integrated TDC (resolution ~ 65 ps)
- self triggered sensor
- pixel $600 \mu\text{m}$ ($\rightarrow 300 \mu\text{m}$)

Development of the sensor in
collaboration with FBK (Trento)

Summary & conclusions

- Particle therapy is becoming a new tool to help oncologist in the multi-approach war to cancer.
- The highly conformal dose release (all hadron) and the high biological efficiency in killing tumor (light ions) gives new treatment possibilities for radio-resistant tumor or seated near organ at risk
- Nuclear fragmentation of the beam prevents the use of ions heavier than Oxygen and must be taken into account in the Treatment Planning System: the nuclear measurements go directly in the clinical practice
- Nuclear fragmentation of target can have an impact on the proton therapy: new measurement/experiment?

Summary & conclusions II

- The nuclear interactions of the beam provide also a method to monitor the released dose, back-tracking the produced secondaries : γ from β^+ emitters, prompt photons from nuclear excitation and light charged fragments
- The neutron production must be carefully measured and taken into account, in particular for pediatric patients: challenge for the detector development

I did not discuss here:

- R&D in the accelerator technologies: very lively field, can change the landscape of the beam that can be embedded in an Hospital, and that an hospital can afford
- The economic part of the story: PT is more expensive than conventional RT, and needs more space (i.e. dedicated centers...). This can change in future but must be taken into account

Applied Radiation Physics Group

G. Battistoni⁷, V. Bocci², F. Collamati^{2,4}, E. De Lucia³,
R. Faccini^{1,2}, F. Ferroni^{1,2}, M. Marafini^{2,5}, I. Mattei⁷, S. Morganti², R. Paramatti²,
V. Patera^{2,4,5}, D. Pinci², L. Recchia², A. Rucinski², A. Russomando^{1,2,6},
A Sarti^{3,4}, A. Sciubba^{5,2,4}, E. Solfaroli Camillocci⁶, M. Toppi³, G. Traini^{1,2}, C. Voena^{1,2}

1. DIPARTIMENTO DI FISICA, SAPIENZA UNIVERSITÀ DI ROMA, ROME, ITALY;
2. INFN SEZIONE DI ROMA, ITALY;
3. LABORATORI NAZIONALI DI FRASCATI DELL'INFN, ITALY;
4. DIPARTIMENTO DI SCIENZE DI BASE E APPLICATE PER INGEGNERIA, SAPIENZA UNIVERSITÀ DI ROMA, ITALY;
5. MUSEO STORICO DELLA FISICA E CENTRO STUDI E RICERCHE 'E. FERMI', ITALY;
6. CENTER FOR LIFE NANO SCIENCE@SAPIENZA, ISTITUTO ITALIANO DI TECNOLOGIA, ITALY;
7. INFN SEZIONE DI MILANO, ITALY;



Oncological application:

- CHIRONE: Probes for radio-guided surgery

Particle therapy activities:

- ✓ Fragmentation measurements (FIRST);
- ✓ Prompt secondaries measurements;
- ✓ INSIDE: dose profiler@CNAO;
- ✓ MONDO: neutron dose measurements;
- ✓ FOOT experiment (??)



GSI Helmholtzzentrum für Schwerionenforschung GmbH



Thanks....

CREDITS

I am in debt for a lot of slides, plots, comments,
discussions and with many colleagues...

U.Amaldi, M.Durante, G.Battistoni, K.Parodi, S.Rossi,
F.Tommasino, M.Marafini
& many others...

Vincenzo Patera

Universita' di Roma "La Sapienza" & INFN
Tor Vergata 11 Nov 2015

